Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

Clinical Cancer Research

Volumn 14, Issue 20, 2008, Pages 6656-6662

  Blay, Jean Yves ^a,b   Von Mehren, Margaret ^c   Samuels, Brian L ^d   Fanucchi, Michael P ^e   Ray Coquard, Isabelle ^b   Buckley, Brigid ^f   Gilles, Leen ^f   Lebedinsky, Claudia ^g   Elsayed, Yusri A ^f   Cesne, Axel Le ^h  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

^c FOX CHASE CANCER CENTER   (United States)

^d North Idaho Cancer Center   (United States)

^e ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^g PHARMAMAR S A   (Spain)

^h INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; POPULATION RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ADOLESCENT; BLOOD; DISEASE FREE SURVIVAL; LEIOMYOSARCOMA; LIPOSARCOMA; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SARCOMA; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIOXOLES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROGNOSIS; SARCOMA; SURVIVAL RATE; TETRAHYDROISOQUINOLINES; YOUNG ADULT;

EID: 58149186082     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0336     Document Type: Article

References (39)

1. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-45.
2. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cis-platin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75.
3. O'Bryan RM, Luce JK, Talley RW,Gottlieb JA, Baker LH, Bonadonna G. Phase II evaluation of Adriamycin in human neoplasia. Cancer 1973;32:1-8.
4. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-7.
5. Le Pechoux C, Pautier P, Delannes M, et al. Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma). Cancer Radiother 2006;10:185-207.
6. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNAmi-nor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-9.
7. Moore BM, Ii FCS,Wheelhouse RT, Hurley LH. Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2. Interac-tions1985;52:375.
8. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-7.
9. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinasci-din-743. Proc Natl Acad Sci U S A 2000;97:6780-4.
10. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6.
11. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-8.
12. Martinez EJ, Corey EJ, Owa T. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 2001;8:1151-60.
13. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeu-tic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001;7: 2908-11.
14. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001;7:3251-7.
15. Izbicka E, Lawrence R, Raymond E, et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 1998;9:981-7.
16. Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-65.
17. Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res 2002;8:75-85.
18. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001;7:231-42.
19. Delaloge S, Yovine A, Taamma A, et al. Ecteinasci-din-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001;19:1248-55.
20. Zelek L, Yovine A, Brain E, et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006;94:1610-4.
21. Yovine A, Riofrio M, Blay J, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-900.
22. Laverdiere C, Kolb E A, Supko JG, et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832-40.
23. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-84.
24. Garcia-Carbonero R, Supko J, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-90.
25. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multi-center phase II and pharmacokinetic study. J Clin Oncol 2005;23:5484-92.
26. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005;23:1867-74.
27. McMeekin DS, Krasner C, Chan S, et al. Final results of a phase II study of weekly trabectedin in second/ third line ovarian carcinoma. ASCO Annu Meet Proc 2005;23:5011.
28. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003;52:131-8.
29. Cohen RB, Schilder RJ, Cheng J, et al. Final results of a combination study between trabectedin and pegylated liposomal doxorubicin (PLD) in patients with advanced malignancies. ASCO Annu Meet Proc;2005.p.3074.
30. National Cancer Institute Common Toxicity Criteria V2.0. Bethesda: National Cancer Institute; 1999.
31. Therasse P, Arbuck SG, Eisenhauer EA, et al.; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
32. Gurtler JS, Goldstein L, Delprete S, et al.Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens. ASCO Annu Meet Proc; 2005. p. 625.
33. McMeekin DS, Manikas G, Crispens M, et al. A phase II study of trabectedin (ET-743) as a second line therapy in patients with persistent or recurrent endometrial carcinoma. ASCO Annu Meet Proc 2004;22:5086.
34. McMeekin DS, del Campo JM, Colombo N, et al. Trabectedin (T) in relapsed advanced ovarian cancer (ROC): a pooled analysis of three phase II studies. ASCO Annu Meet Proc Part I 2007;25:5579.
35. Del Campo J, Roszak A, Ciuleanu T, et al. Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. ASCO Annu Meet Proc 2006;24:5031.
36. Del Campo J, Roszak A, Ciuleanu T, et al. Randomized phase II open-label study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive recurrent ovarian carcinoma: preliminary results. Chemotherapy Foundation Symposium XXIV; NewYork,NY; 2006 Nov8-11.
37. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-9.
38. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pre-treated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602.
39. Benjamin RS. Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) as surrogates for survival and time to progression. J Clin Oncol 2006;24:9506.